Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Mol Cancer ; 22(1): 63, 2023 03 30.
Article in English | MEDLINE | ID: mdl-36991428

ABSTRACT

BACKGROUND: Although metastasis is the foremost cause of cancer-related death, a specialized mechanism that reprograms anchorage dependency of solid tumor cells into circulating tumor cells (CTCs) during metastatic dissemination remains a critical area of challenge. METHODS: We analyzed blood cell-specific transcripts and selected key Adherent-to-Suspension Transition (AST) factors that are competent to reprogram anchorage dependency of adherent cells into suspension cells in an inducible and reversible manner. The mechanisms of AST were evaluated by a series of in vitro and in vivo assays. Paired samples of primary tumors, CTCs, and metastatic tumors were collected from breast cancer and melanoma mouse xenograft models and patients with de novo metastasis. Analyses of single-cell RNA sequencing (scRNA-seq) and tissue staining were performed to validate the role of AST factors in CTCs. Loss-of-function experiments were performed by shRNA knockdown, gene editing, and pharmacological inhibition to block metastasis and prolong survival. RESULTS: We discovered a biological phenomenon referred to as AST that reprograms adherent cells into suspension cells via defined hematopoietic transcriptional regulators, which are hijacked by solid tumor cells to disseminate into CTCs. Induction of AST in adherent cells 1) suppress global integrin/ECM gene expression via Hippo-YAP/TEAD inhibition to evoke spontaneous cell-matrix dissociation and 2) upregulate globin genes that prevent oxidative stress to acquire anoikis resistance, in the absence of lineage differentiation. During dissemination, we uncover the critical roles of AST factors in CTCs derived from patients with de novo metastasis and mouse models. Pharmacological blockade of AST factors via thalidomide derivatives in breast cancer and melanoma cells abrogated CTC formation and suppressed lung metastases without affecting the primary tumor growth. CONCLUSION: We demonstrate that suspension cells can directly arise from adherent cells by the addition of defined hematopoietic factors that confer metastatic traits. Furthermore, our findings expand the prevailing cancer treatment paradigm toward direct intervention within the metastatic spread of cancer.


Subject(s)
Breast Neoplasms , Lung Neoplasms , Melanoma , Neoplastic Cells, Circulating , Mice , Animals , Humans , Female , Cell Line, Tumor , Neoplastic Cells, Circulating/pathology , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Melanoma/metabolism , Lung Neoplasms/pathology , Neoplasm Metastasis
3.
Sci Rep ; 8(1): 17717, 2018 12 07.
Article in English | MEDLINE | ID: mdl-30531928

ABSTRACT

15-hydroxyprostaglandin dehydrogenase (15-PGDH), the rate-limiting enzyme in prostaglandin E2 degradation, is decreased in gastric cancers and microRNA (miR)-21 is one of the regulators. We investigated the expression and regulation of 15-PGDH in eary gastric carcinogenesis utilizing endoscopic submucosal dissection (ESD) and gastric cancer cell lines. Expression of 15-PGDH and cyclooxygenase-2 as well as the promoter methylation of 15-PGDH were evaluted. CRISPR, miR-21 transfection, proliferation and apoptosis assays were also done. We observed significant decreases in 15-PGDH expression but no promoter methylation was detected in any ESDs. 15-PGDH suppression by CRISPR induced enhanced growth kinetics. miR-21, which was detected in high level in gastric tumors from the TGCA data, caused increased proliferation, decreased apoptosis. miR-21 overexpression was confirmed with CISH and RT-PCR in the ESDs. Loss of 15-PGDH occurs at the very early stage of gastric adenocarcinoma by miR-21. H. pylori infection may affect miR-21 up regulation. Maintaining 15-PGDH enzyme activity could be a new strategic measure in preventing gastric cancer especially tubular adenocarcinoma.


Subject(s)
Adenocarcinoma/genetics , Hydroxyprostaglandin Dehydrogenases/genetics , MicroRNAs/genetics , Stomach Neoplasms/genetics , Apoptosis/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Clustered Regularly Interspaced Short Palindromic Repeats/genetics , Cyclooxygenase 2/genetics , Dinoprostone/genetics , Gene Expression Regulation, Enzymologic/genetics , Gene Expression Regulation, Neoplastic , Helicobacter Infections/genetics , Humans , Methylation , Promoter Regions, Genetic/genetics , Prospective Studies , Retrospective Studies , Transfection/methods
4.
Sci Rep ; 8(1): 11314, 2018 07 27.
Article in English | MEDLINE | ID: mdl-30054522

ABSTRACT

Owing to the recent progress in regenerative medicine technology, clinical trials that harnessed the regeneration and immune modulation potentiality of stem cells for treating IBD have shown promising results. We investigated the feasibility and utility of intraluminal endoscopic transplantation of rat MSC sheets in murine models of experimental colitis for targeted delivery of stem cells to lesions. We isolated adipose-derived mesenchymal stem cells (AD-MSC) and bone marrow-derived mesenchymal stem cells (BM-MSC) from EGFP-transgenic rats and fabricated the cells in sheet forms using temperature-responsive culture dishes. The MSC sheets were endoscopically transplanted to the inflamed area in electrocoagulation and DNBS colitis model. The effect of the transplantation was verified using endoscopic scoring and histological analysis. In the electrocoagulation model, the AD-MSC group showed significantly decreased ulcer size in the transplanted regions. In the DNBS colitis model, the AD-MSC group showed decreased inflammation and colitis in the transplanted regions. Histologic analysis showed that the MSC sheets had successfully attached to the inflamed mucosa in both the electrocoagulation and DNBS colitis model. Our results show that endoscopic transplantation of MSC sheets could be a new effective mode of stem cell therapy for IBD treatment.


Subject(s)
Colitis/therapy , Inflammation/therapy , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Animals , Colitis/chemically induced , Colitis/genetics , Colitis/pathology , Dinitrofluorobenzene/analogs & derivatives , Dinitrofluorobenzene/toxicity , Disease Models, Animal , Endoscopes , Green Fluorescent Proteins/genetics , Humans , Inflammation/chemically induced , Inflammation/genetics , Inflammation/pathology , Mice , Rats , Rats, Transgenic/genetics
5.
Eur J Pharmacol ; 794: 1-7, 2017 Jan 05.
Article in English | MEDLINE | ID: mdl-27845068

ABSTRACT

Western-style diet (WD) and dysbiosis are known to be associated with colonic inflammation, which contributes to carcinogenesis. Metformin (Met) exerts anti-inflammatory effects to induce AMP-activated protein kinase (AMPK), resulting in suppressed protein synthesis and reduced cell proliferation. Probiotic VSL#3 (V) modifies microbial composition. We investigated the chemopreventive mechanisms of Met and V in WD-induced colitis-associated colon carcinogenesis. Male BALB/c mice were randomly divided into five groups: a control diet (CD) group, WD group, WD+ Met (250mg/kg/day) group, WD+V (1.3 million bacteria/day) group, and WD+Met+V group. All mice were exposed to azoxymethane (10mg/kg) followed by 2% dextran sodium sulfate (DSS) for 7 days. Using HCT-116 human colon cancer cell line, expression of AMPK, extracellular signal-regulated kinase (ERK), cyclin D1, and Bcl-2 was investigated and cell cycle arrest was assessed. WD enhanced the severity of colitis and tumor growth compared with CD. The combination of Met and V significantly ameliorated colitis and tumor growth by inhibiting macrophage infiltration and maintaining epithelial integrity. In vitro assays showed that the combination therapy promoted late apoptosis by inhibiting cyclin D1 and Bcl-2 and activating pro-apoptotic ERK. A combination therapy with Met and V attenuates tumor growth in a mouse model of WD-induced colitic cancer, suggesting that this strategy could be useful for the chemoprevention of colon cancer.


Subject(s)
Colonic Neoplasms/prevention & control , Diet, Western/adverse effects , Metformin/pharmacology , Probiotics/pharmacology , AMP-Activated Protein Kinases/metabolism , Animals , Carcinogenesis/drug effects , Cell Proliferation/drug effects , Colitis/complications , Colonic Neoplasms/chemically induced , Colonic Neoplasms/complications , Colonic Neoplasms/pathology , Cyclin D1/antagonists & inhibitors , Drug Synergism , Enzyme Activation/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Macrophages/drug effects , Macrophages/immunology , Male , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...